GSK-690693

Alias: GSK690693; GSK 690693; GSK-690693
Cat No.:V0157 Purity: ≥98%
GSK690693, an aminofurazan derivative, is a novel, potent andATP-competitivepan-Akt inhibitor targeting Akt1/2/3 with potential anticancer activity.
GSK-690693 Chemical Structure CAS No.: 937174-76-0
Product category: Akt
This product is for research use only, not for human use. We do not sell to patients.
Size Price Stock Qty
1mg
5mg
10mg
25mg
50mg
100mg
250mg
Other Sizes

Other Forms of GSK-690693:

  • AKT Kinase Inhibitor
Official Supplier of:
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Top Publications Citing lnvivochem Products
Purity & Quality Control Documentation

Purity: ≥98%

Product Description

GSK690693, an aminofurazan derivative, is a novel, potent and ATP-competitive pan-Akt inhibitor targeting Akt1/2/3 with potential anticancer activity. With IC50 values of 2 nM, 13 nM, and 9 nM in cell-free assays, it inhibits Akt1/2/3. GSK690693's antiproliferative effects were specific to cancer cells because it had no effect on the growth of healthy mouse thymocytes or normal human CD4(+) peripheral T lymphocytes. GSK690693 treatment decreased the phosphorylation of downstream AKT substrates in both sensitive and insensitive cell lines, indicating that the lack of AKT kinase inhibition was not the root cause of resistance.

Biological Activity I Assay Protocols (From Reference)
Targets
Akt1 (IC50 = 2 nM); Akt3 (IC50 = 9 nM); Akt2 (IC50 = 13 nM); PKCη (IC50 = 2 nM); PKCθ (IC50 = 2 nM); PrkX (IC50 = 5 nM); PAK6 (IC50 = 6 nM); PAK4 (IC50 = 10 nM); PKCδ (IC50 = 14 nM); PKCβ1 (IC50 = 19 nM); PKCε (IC50 = 21 nM); PKA (IC50 = 24 nM); PKG1β (IC50 = 33 nM); AMPK (IC50 = 50 nM); PAK5 (IC50 = 52 nM); DAPK3 (IC50 = 81 nM); Autophagy
ln Vitro
GSK690693 is very selective for the Akt isoforms versus the majority of kinases in other families. With IC50 values of 24 nM, 5 nM, and 2-21 nM, respectively, GSK690693 is less selective for AGC kinase family members such as PKA, PrkX, and PKC isozymes. Additionally, PAK4, 5, and 6 from the STE family have IC50 values of 10 nM, 52 nM, and 6 nM, respectively. GSK690693 also potently inhibits AMPK and DAPK3 from the CAMK family. With an IC50 ranging from 43 nM to 150 nM, GSK690693 prevents tumor cells from phosphorylating GSK3. The nuclear accumulation of the transcription factor FOXO3A is increased dose-dependently by treatment with GSK690693. The IC50 values for GSK690693 are as follows: 72 nM, 79 nM, 86 nM, 119 nM, 975 nM, and 147 nM for T47D, ZR-75-1, BT474, HCC1954, MDA-MB-453, and LNCaP cells, respectively. In both LNCaP and BT474 cells, treatment with GSK690693 induces apoptosis at concentrations >100 nM. [1] GSK690693 induces apoptosis in susceptible ALL cell lines, supporting the function of AKT in cell survival.[2]
ln Vivo
GSK690693 inhibits GSK3 phosphorylation in human breast carcinoma (BT474) xenografts in a dose- and time-dependent manner after a single administration. The Akt substrates PRAS40 and FKHR/FKHRL1 are reduced in phosphorylation when GSK690693 is administered. Blood glucose levels are also acutely elevated by GSK690693 but return to normal 8 to 10 hours later. The growth of human SKOV-3 ovarian, LNCaP prostate, and BT474 and HCC-1954 breast carcinoma xenografts is potently inhibited by the administration of GSK690693, with a maximal inhibition of 58% to 75% at the dose of 30 mg/kg/day.[1] GSK690693 is effective regardless of the Akt activation mechanism at play. When administered to Lck-MyrAkt2 mice, which express a membrane-bound, constitutively active form of Akt, GSK690693 slows the progression of tumors the best. [3]
Enzyme Assay
Expressed and purified from baculovirus is full-length Akt1, 2, or 3 that has been His-tagged. Purified PDK1 and MK2, which phosphorylate Ser473 and Thr308, respectively, are used to activate the protein. Activated Akt enzymes are incubated with GSK690693 at varying concentrations at room temperature for 30 minutes prior to the addition of substrate to start the reaction in order to more precisely measure time-dependent inhibition of Akt. Final reaction contains 5 nM to 15 nM Akt1, 2, and 3 enzymes; 2 μM ATP; 0.15 μCi/μL[γ-33P]ATP; 1 μM Peptide (Biotin-aminohexanoicacid-ARKR-ERAYSFGHHA-amide); 10 mM MgCl2; 25 mM MOPS (pH 7.5); 1 mM DTT; 1 mM CHAPS; and 50 mM KCl. The reactions are allowed to sit for 45 minutes at room temperature before being stopped with Leadseeker beads in PBS containing EDTA (2 mg/mL beads at a final concentration of 75 mM EDTA). The plates are next sealed, the beads are given at least 5 hours to settle, and a Viewlux Imager is used to quantify product formation.
Cell Assay
Cells are plated at densities that allow untreated cells to grow logarithmically during the course of a 3-day assay. Briefly, cells are plated in 96- or 384-well plates and incubated overnight. Cells are then treated with GSK690693 (ranging from 30 μM-1.5 nM) and incubated for 72 hours. Cell proliferation is measured using the CellTiter Glo reagent. Data are analyzed using the XLFit curve-fitting tool for Microsoft Excel. IC50 values are obtained by fitting data to Eq, 2.
Animal Protocol
In 8–12-week-old CD1 Swiss Nude mice (LNCaP, SKOV-3, and PANC1) or SCID mice (HCC1954, MDA-MB-453, and BT474), tumors are induced by subcutaneous injection of tumor cell suspension (HCC1954, MDA-MB-453, and LNCaP) or tumor fragments (BT474, SKOV-3, and PANC1) or tumor fragments. A randomization procedure is used to divide the mice into groups of 8–12 mice each once tumors reach a volume of 100–200 mm3. A dose of 10, 20, or 30 mg/kg of GSK690693 is given intravenously once daily. At the end of the experiment, animals are put to death by CO2 inhalation. Using calipers and the formula tumor volume (mm3)=(length width2)/2, tumor volume is calculated twice per week. Results are presented as% inhibition on day 21 of treatment=100 [1-(average growth of the drug-treated population/average growth of the vehicle-treated control population)]. The two-tailed t test is used for statistical analysis.
References

[1]. Cancer Res. 2008 Apr 1;68(7):2366-74.

[2]. Blood. 2009 Feb 19;113(8):1723-9.

[3]. Clin Cancer Res. 2010 Jan 15;16(2):486-96.

These protocols are for reference only. InvivoChem does not independently validate these methods.
Physicochemical Properties
Molecular Formula
C21H27N7O3
Molecular Weight
425.4842
Exact Mass
425.2175
Elemental Analysis
C, 59.28; H, 6.40; N, 23.04; O, 11.28
CAS #
937174-76-0
Appearance
Solid powder
SMILES
CCN1C2=C(C(=NC=C2OC[C@H]3CCCNC3)C#CC(C)(C)O)N=C1C4=NON=C4N
InChi Key
KGPGFQWBCSZGEL-ZDUSSCGKSA-N
InChi Code
InChI=1S/C21H27N7O3/c1-4-28-18-15(30-12-13-6-5-9-23-10-13)11-24-14(7-8-21(2,3)29)16(18)25-20(28)17-19(22)27-31-26-17/h11,13,23,29H,4-6,9-10,12H2,1-3H3,(H2,22,27)/t13-/m0/s1
Chemical Name
4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-[[(3S)-piperidin-3-yl]methoxy]imidazo[4,5-c]pyridin-4-yl]-2-methylbut-3-yn-2-ol
Synonyms
GSK690693; GSK 690693; GSK-690693
HS Tariff Code
2934.99.9001
Storage

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

Shipping Condition
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
Solubility Data
Solubility (In Vitro)
DMSO: ~39 mg/mL (~91.7 mM)
Water: <1 mg/mL
Ethanol: <1 mg/mL
Solubility (In Vivo)
15% Captisol: 30mg/mL (Please use freshly prepared in vivo formulations for optimal results.)
Preparing Stock Solutions 1 mg 5 mg 10 mg
1 mM 2.3503 mL 11.7514 mL 23.5029 mL
5 mM 0.4701 mL 2.3503 mL 4.7006 mL
10 mM 0.2350 mL 1.1751 mL 2.3503 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.

Calculator

Molarity Calculator allows you to calculate the mass, volume, and/or concentration required for a solution, as detailed below:

  • Calculate the Mass of a compound required to prepare a solution of known volume and concentration
  • Calculate the Volume of solution required to dissolve a compound of known mass to a desired concentration
  • Calculate the Concentration of a solution resulting from a known mass of compound in a specific volume
An example of molarity calculation using the molarity calculator is shown below:
What is the mass of compound required to make a 10 mM stock solution in 5 ml of DMSO given that the molecular weight of the compound is 350.26 g/mol?
  • Enter 350.26 in the Molecular Weight (MW) box
  • Enter 10 in the Concentration box and choose the correct unit (mM)
  • Enter 5 in the Volume box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 17.513 mg appears in the Mass box. In a similar way, you may calculate the volume and concentration.

Dilution Calculator allows you to calculate how to dilute a stock solution of known concentrations. For example, you may Enter C1, C2 & V2 to calculate V1, as detailed below:

What volume of a given 10 mM stock solution is required to make 25 ml of a 25 μM solution?
Using the equation C1V1 = C2V2, where C1=10 mM, C2=25 μM, V2=25 ml and V1 is the unknown:
  • Enter 10 into the Concentration (Start) box and choose the correct unit (mM)
  • Enter 25 into the Concentration (End) box and select the correct unit (mM)
  • Enter 25 into the Volume (End) box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 62.5 μL (0.1 ml) appears in the Volume (Start) box
g/mol

Molecular Weight Calculator allows you to calculate the molar mass and elemental composition of a compound, as detailed below:

Note: Chemical formula is case sensitive: C12H18N3O4  c12h18n3o4
Instructions to calculate molar mass (molecular weight) of a chemical compound:
  • To calculate molar mass of a chemical compound, please enter the chemical/molecular formula and click the “Calculate’ button.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
  • Molecular mass (or molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
  • Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
/

Reconstitution Calculator allows you to calculate the volume of solvent required to reconstitute your vial.

  • Enter the mass of the reagent and the desired reconstitution concentration as well as the correct units
  • Click the “Calculate” button
  • The answer appears in the Volume (to add to vial) box
In vivo Formulation Calculator (Clear solution)
Step 1: Enter information below (Recommended: An additional animal to make allowance for loss during the experiment)
Step 2: Enter in vivo formulation (This is only a calculator, not the exact formulation for a specific product. Please contact us first if there is no in vivo formulation in the solubility section.)
+
+
+

Calculation results

Working concentration mg/mL;

Method for preparing DMSO stock solution mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.

Method for preparing in vivo formulation:Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.

(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
             (2) Be sure to add the solvent(s) in order.

Clinical Trial Information
NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT00666081 Withdrawn Drug: GSK690693 Cancer GlaxoSmithKline April 2008 Phase 1
NCT00493818 Terminated Drug: GSK690693 Cancer GlaxoSmithKline April 2007 Phase 1
Biological Data
  • GSK690693
  • GSK690693
Contact Us